Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH
- PMID: 30361244
- PMCID: PMC6446239
- DOI: 10.1183/13993003.01297-2018
Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH
Abstract
Cystic fibrosis (CF) is a recessive genetic disease that is characterised by airway mucus plugging and reduced mucus clearance. There are currently alternative hypotheses that attempt to describe the abnormally viscous and elastic mucus that is a hallmark of CF airways disease, including: 1) loss of CF transmembrane regulator (CFTR)-dependent airway surface volume (water) secretion, producing mucus hyperconcentration-dependent increased viscosity, and 2) impaired bicarbonate secretion by CFTR, producing acidification of airway surfaces and increased mucus viscosity.A series of experiments was conducted to determine the contributions of mucus concentration versus pH to the rheological properties of airway mucus across length scales from the nanoscopic to macroscopic.For length scales greater than the nanoscopic, i.e. those relevant to mucociliary clearance, the effect of mucus concentration dominated over the effect of airway acidification.Mucus hydration and chemical reduction of disulfide bonds that connect mucin monomers are more promising therapeutic approaches than alkalisation.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: D.B. Hill reports grants from Cystic Fibrosis Foundation, National Science Foundation and National Institutes of Health, during the conduct of the study. Conflict of interest: R.F. Long has nothing to disclose. Conflict of interest: W.J. Kissner reports grants from NIH National Institute of Diabetes, Digestive, and Kidney Diseases (federal), National Science Foundation (federal), KNOW Bio, LLC (business and industry), NIH National Heart, Lung, and Blood Institute (federal), Cystic Fibrosis Foundation (foundation) and Cystic Fibrosis Foundation Therapeutics (foundation), during the conduct of the study. Conflict of interest: E. Atieh has nothing to disclose. Conflict of interest: I.C. Garbarine reports grants from Cystic Fibrosis Foundation, during the conduct of the study. Conflict of interest: M.R. Markovetz has nothing to disclose. Conflict of interest: N.C. Fontana has nothing to disclose. Conflict of interest: M. Christy has nothing to disclose. Conflict of interest: M. Habibpour has nothing to disclose. Conflict of interest: R. Tarran has nothing to disclose. Conflict of interest: M.G. Forest has nothing to disclose. Conflict of interest: R.C. Boucher is chairman of the board of Parion Sciences, a privately held UNC spin-out company focused on developing therapies for CF, and has equity in the company and received monetary compensation as board chair. Conflict of interest: B. Button has nothing to disclose.
Figures
References
-
- Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008: 70: 459–486. - PubMed
-
- Boucher RC. An overview of the pathogenesis of c1ystic fibrosis lung disease. Adv Drug Deliv Rev 2002; 54(11): 1359–1371. - PubMed
-
- Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Resp J 2004: 23(1): 146–158. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical